Avelumab (anti-PD-L1) PD-1/PD-L1 inhibitor | Read Reviews & Product Use Citations

Avelumab (anti-PD-L1) (MSB0010718C) is a fully human IgG1 monoclonal antibody that targets the protein programmed death-ligand 1 (PD-L1). Avelumab exhibits potential antibody-dependent cell-mediated cytotoxicity and is used for the treatment of several kinds of carcinoma. MW=143.8 kDa.

Click to purchase the isotype control of Avelumab (anti-PD-L1)

2 Citations

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99.99% Protein concentration: 3.2mg/ml Endotoxin Level: ＜1EU/mg

99.99

Specificity

Name	Citation	PD-1/PD-L1 interaction	PD-1	PD-L1	PD-1/PD-L1	Others
GS-4224	0	++++			++++
INCB086550	1	++			++
BMS-1001	0	+			+
BMS-1166	8	+++
PD-1/PD-L1 Inhibitor 3	13	+++
BMS-1	13	++
BMS202	26	+
CA-170 (AUPM-170)	0			✔
SR 0987	1		✔			IL17,RORγt
Spartalizumab (anti-PD-1)	3		✔
Camrelizumab (anti-PD-1)	2		✔
AUNP-12	3			✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Avelumab (anti-PD-L1) (MSB0010718C) is a fully human IgG1 monoclonal antibody that targets the protein programmed death-ligand 1 (PD-L1). Avelumab exhibits potential antibody-dependent cell-mediated cytotoxicity and is used for the treatment of several kinds of carcinoma. MW=143.8 kDa.
In vitro	Co-incubating chordoma cells with brachyury-specific CD8+ T cells results in significant upregulation of PD-L1 on the tumor cells, mediated by the CD8+ T cells' IFN-γ production, and increases sensitivity of chordoma cells to avelumab-mediated ADCC. Residential cancer stem cell subpopulations of chordoma cells are also killed by avelumab-mediated ADCC to the same degree as non-cancer stem cell populations. As a monotherapy for chordoma, avelumab may enable endogenous NK cells, while in combination with T-cell immunotherapy, such as a vaccine, avelumab may enhance NK-cell killing of chordoma cells via ADCC.
Cell Research	Objective: Antibody-dependent cellular cytotoxicity assay Cells: UM-Chor1 cells Concentrations: 2 μg/mL Incubation Time: 30 min Method: To examine the relationship between a CSC subpopulation and ADCC activity, UM-Chor1 cells are left untreated or treated with 50 ng/mL of IFN-γ for 24 h. Cells are then plated as targets at 50,000 cells/well in 6-well round-bottom culture plates and incubated with 2 μg/mL of avelumab at room temperature for 30 min. NK cells are added at 2500,000 cells/well at an E:T ratio of 50:1. After 4 h, tumor cells are harvested and stained with antibodies for flow cytometry. Reference: https://pubmed.ncbi.nlm.nih.gov/27172898 Avelumab can apply to humanized mice, non-humanized mice (eg: C57BL/6 mice), peripheral blood and other related assays (Only for Reference)
In vivo	An aggressive, bioluminescent orthotopic bladder cancer model, MB49 tumor cells transfected with luciferase (MB49^luc) is used to study the antitumor effects of avelumab. MB49^luc bladder tumors are highly positive for the expression of PD-L1 and avelumab administration induces significant (P<0.05) antitumor effects.
Animal Research	Objective: Measurement of individual tumors Animal Models: 16- to 18-week-old female C57BL/6 mice Formulation: DPBS Dosages: 400 μg/100 μL Administration: i.p. Reference: https://pubmed.ncbi.nlm.nih.gov/26921031/ Avelumab can apply to humanized mice, non-humanized mice (eg: C57BL/6 mice), peripheral blood and other related assays (Only for Reference)
References	[1] https://pubmed.ncbi.nlm.nih.gov/27172898/ [2] https://pubmed.ncbi.nlm.nih.gov/26921031/

Product Details

CAS No.	1537032-82-8
Isotype	Human IgG1
Source	Human
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20 mM Arg, pH 5.0
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.